Omeros Corp (OMER) Stock Price, Quote & News

Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has...

Industry: Biotechnology

Sector: Healthcare

Phone: 206 676 5000

Website: www.omeros.com

Address:

The Omeros Building, 201 Elliott Avenue West, Seattle, United States

721DiamondHands Mar. 18 at 9:09 PM

$OMER Leonard Bell retired after 25 years net worth 425million ceo of alexion,If i were Greg Id sell to the highest bidder and enjoy life and family,Lifes too short especially as you get older.I would not wait 5 years,2 years not even a year,Thats just me tho!

2 · Reply

naturegirl669 Mar. 18 at 7:26 PM

$OMER - "A prospective, screening strategy in adults receiving first allogeneic HCT at 3 centers showed a 21.8% incidence of severe TA-TMA." "Patients with severe TA-TMA have significantly higher nonrelapse and overall mortality than patients with nonsevere and no TA-TMA." https://ashpublications.org/blood/article-abstract/146/5/638/537044/High-incidence-of-severe-TA-TMA-increases?redirectedFrom=fulltext

1 · Reply

banditbandit Mar. 18 at 7:22 PM

$OMER HOLY SHIT JUST GO UP YOU FUCKING FLAMING TURD HOLY SHIT JUST GO UP YOU FUCKING FLAMING TURD HOLY SHIT JUST GO UP YOU FUCKING FLAMING TURD HOLY SHIT JUST GO UP YOU FUCKING FLAMING TURD HOLY SHIT JUST GO UP YOU FUCKING FLAMING TURD HOLY SHIT JUST GO UP YOU FUCKING FLAMING TURD HOLY SHIT JUST GO UP YOU FUCKING FLAMING TURD HOLY SHIT JUST GO UP YOU FUCKING FLAMING TURD HOLY SHIT JUST GO UP YOU FUCKING FLAMING TURDHOLY SHIT JUST GO UP YOU FUCKING FLAMING TURD :)

1 · Reply

AgentMulder Mar. 18 at 7:21 PM

$OMER Damn, yet another buying opportunity😂😂😂👊

1 · Reply

mjk49 Mar. 18 at 7:11 PM

$OMER added

0 · Reply

WinstonWolfff Mar. 18 at 7:05 PM

$OMER Dump truck at work....

0 · Reply

mjk49 Mar. 18 at 4:06 PM

$OMER we don’t go up with market but we go down with it.

0 · Reply

Tyler1100 Mar. 18 at 3:45 PM

$OMER have they announced when Earnings will be released

1 · Reply

resq1 Mar. 18 at 3:42 PM

$OMER cost basis under $8 for most us longs. But still frustrating to see the rug pull on weaker hands

1 · Reply

Phase3 Mar. 18 at 3:40 PM

$OMER Grabbed some right here.

1 · Reply

Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program

Jan 27, 2026, 9:00 AM EST - 7 weeks ago

Omeros Announces First Commercial Sales of YARTEMLEA®

Jan 7, 2026, 9:07 PM EST - 2 months ago

Omeros Corporation (OMER) Discusses FDA Approval and Commercialization Plans for YARTEMLEA in TA-TMA Treatment Transcript

Jan 7, 2026, 6:50 PM EST - 2 months ago

Omeros prices transplant complication drug at $36,000 per dose

Dec 26, 2025, 6:36 PM EST - 2 months ago

Omeros Announces New Date for YARTEMLEA® Approval Conference Call

Dec 24, 2025, 2:14 PM EST - 3 months ago

Omeros: Stock Pops On Yartemlea Approval, Longer-Term Upside Likely

Dec 24, 2025, 12:21 PM EST - 3 months ago

Gold Edges Lower; Omeros Shares Jump

AAAU BAR DBP GLD GLDM IAU OUNZ

Dec 24, 2025, 9:05 AM EST - 3 months ago

US FDA approves Omeros' drug to treat dangerous transplant complication

Dec 24, 2025, 9:00 AM EST - 3 months ago

FDA Approves Omeros' YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

Dec 1, 2025, 8:30 AM EST - 3 months ago

Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)

Nov 17, 2025, 10:37 AM EST - 4 months ago

Omeros Corporation (OMER) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 4:11 PM EST - 4 months ago

Omeros Corporation Reports Third Quarter 2025 Financial Results

Nov 11, 2025, 8:30 AM EST - 4 months ago

Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025

Oct 17, 2025, 4:43 PM EDT - 5 months ago

Omeros: Novo Nordisk Deal Highlights MASP-3 Alternative Pathway Targeting

Oct 16, 2025, 10:08 AM EDT - 5 months ago

Omeros: Novo Nordisk's Licensing Deal Sends Shares Soaring, Makes Bull Case

NVO

Oct 16, 2025, 8:30 AM EDT - 5 months ago

Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group

Oct 15, 2025, 2:58 PM EDT - 5 months ago

Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal

NVO

Oct 15, 2025, 11:54 AM EDT - 5 months ago

Can OMER stock retain Novo Nordisk driven gains over the long-term?

Oct 15, 2025, 9:17 AM EDT - 5 months ago

Novo Nordisk to Pay Omeros Up to $2.1 Billion For Blood Disease Drug

NVO

Oct 15, 2025, 8:32 AM EDT - 5 months ago

Novo Nordisk signs up to $2.1 billion licensing deal with Omeros in rare disease push

NVO

Oct 15, 2025, 8:30 AM EDT - 5 months ago

Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros' clinical-stage MASP-3 inhibitor zaltenibart (OMS906)

Sep 2, 2025, 8:45 AM EDT - 7 months ago

Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program

Aug 19, 2025, 4:41 PM EDT - 7 months ago

Omeros Corporation (OMER) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 4:02 PM EDT - 7 months ago

Omeros Corporation Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 4:02 PM EDT - 7 months ago

Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025

Jul 25, 2025, 8:00 AM EDT - 8 months ago

Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering

Jun 27, 2025, 8:30 AM EDT - 9 months ago

Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA

Jun 24, 2025, 8:30 AM EDT - 9 months ago

Omeros Announces Webcast Details for Annual Meeting of Shareholders

Jun 10, 2025, 12:53 PM EDT - 10 months ago

Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision

May 27, 2025, 11:12 PM EDT - 10 months ago

Omeros: On The Brink As It Awaits Its Fall PDUFA For A Potential Blockbuster

May 15, 2025, 9:07 PM EDT - 10 months ago

Omeros Corporation (OMER) Q1 2025 Earnings Conference Call Transcript

May 15, 2025, 4:05 PM EDT - 10 months ago

Omeros Corporation Reports First Quarter 2025 Financial Results

May 12, 2025, 5:05 PM EDT - 11 months ago

Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025

May 12, 2025, 10:35 AM EDT - 11 months ago

Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026

May 6, 2025, 9:16 AM EDT - 11 months ago

FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date

Apr 11, 2025, 3:06 PM EDT - 1 year ago

Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight

Apr 10, 2025, 9:10 AM EDT - 1 year ago

Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros' Proprietary OncotoX-AML Clinical Program

Apr 8, 2025, 9:00 AM EDT - 1 year ago

Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases

Mar 31, 2025, 8:57 PM EDT - 1 year ago

Omeros Corporation (OMER) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 4:02 PM EDT - 1 year ago

Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results

Mar 28, 2025, 7:39 AM EDT - 1 year ago

Top Wall Street Forecasters Revamp Omeros Price Expectations Ahead Of Q4 Earnings

Mar 26, 2025, 9:15 AM EDT - 1 year ago

Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025

Mar 21, 2025, 9:15 AM EDT - 1 year ago

Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program

Feb 24, 2025, 4:44 PM EST - 1 year ago

Omeros Corporation: Scientifically Compelling Again, But The Delay Has Cost Us

Feb 20, 2025, 9:10 AM EST - 1 year ago

Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA

Feb 14, 2025, 9:00 AM EST - 1 year ago

Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings

Feb 10, 2025, 9:00 AM EST - 1 year ago

Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program

Jan 16, 2025, 9:15 AM EST - 1 year ago

Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint

Dec 19, 2024, 12:28 PM EST - 1 year ago

Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges

Dec 19, 2024, 9:15 AM EST - 1 year ago

Omeros' Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA

721DiamondHands Mar. 18 at 9:09 PM

2 · Reply

naturegirl669 Mar. 18 at 7:26 PM

1 · Reply

banditbandit Mar. 18 at 7:22 PM

1 · Reply

AgentMulder Mar. 18 at 7:21 PM

$OMER Damn, yet another buying opportunity😂😂😂👊

1 · Reply

mjk49 Mar. 18 at 7:11 PM

$OMER added

0 · Reply

WinstonWolfff Mar. 18 at 7:05 PM

$OMER Dump truck at work....

0 · Reply

mjk49 Mar. 18 at 4:06 PM

$OMER we don’t go up with market but we go down with it.

0 · Reply

Tyler1100 Mar. 18 at 3:45 PM

$OMER have they announced when Earnings will be released

1 · Reply

resq1 Mar. 18 at 3:42 PM

$OMER cost basis under $8 for most us longs. But still frustrating to see the rug pull on weaker hands

1 · Reply

Phase3 Mar. 18 at 3:40 PM

$OMER Grabbed some right here.

1 · Reply

MinnieSteve3 Mar. 18 at 3:28 PM

$OMER Looks like Friday's $11 options are in the crosshairs.

1 · Reply

Option_trader11 Mar. 18 at 3:26 PM

$OMER 11 was key level.. need to reclaim that otherwise it could drop a bit before earnings 🤐

0 · Reply

LeaLeb Mar. 18 at 2:34 PM

$OMER I bought more under 11.

1 · Reply

Option_trader11 Mar. 18 at 2:32 PM

$OMER do it

0 · Reply

resq1 Mar. 18 at 5:08 AM

$OMER at least the primates have our back

2 · Reply

DragonAlgo Mar. 18 at 5:00 AM

🐉 $OMER CALL — DragonAlgo® Signal Contract: OMER CALL Expiry: 2026-03-20 | Strike: $10.00 | Type: CALL Option Plan (premium): Entry: $1.26 Stop: $0.91 TP1: $1.64 TP2: $2.14 TP3: $3.02 Momentum tape remains active. 🔗 https://dragonalgo.com

0 · Reply

mjk49 Mar. 18 at 4:03 AM

$OMER

0 · Reply

bentley99 Mar. 17 at 9:25 PM

$OMER Something soon. Large spam campaign on X right now.

2 · Reply

Stoxx4fun Mar. 17 at 8:44 PM

$OMER Chairs and presenters of the below event have all been investigating OMS721. E13 Educational | Endothelial dysfunction syndromes - A focus on TA-TMA https://ebmt2026.abstractserver.com/programme/#/details/sessions/102

0 · Reply

WinstonWolfff Mar. 17 at 8:05 PM

$OMER Nice close and above average AH volume.

1 · Reply

resq1 Mar. 17 at 6:16 PM

$OMER something leaked

2 · Reply

LowCountry15 Mar. 17 at 6:02 PM

$OMER Remember what HC Wainwright published? Q1: $0 Q2: $700K Q3: $2.8 Q4: $10.3 The bar is low…could we cover all ‘26 in this quarter alone??

1 · Reply

Market Cap	793.37M
Revenue (ttm)	0.00
Net Income (ttm)	-156.82M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-0.80

Volume	778,108
Avg Vol	1,545,114
Day's Range	N/A - N/A
Shares Out	70.90M
Stochastic %K	27%
Beta	2.45
Analysts	Sell
Price Target	$43.67